143782-23-4: Enzalutamide Impurity 2
It is a nonsteroidal antiandrogen that binds to the ligand-binding domain and has more affinity. It is used in the treatment of castration-resistant prostate cancer.
Additional information on CAS 143782-23-4
"Schrader, Andres Jan, et al. “Enzalutamide in Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel and Abiraterone.” European Urology, vol. 65, no. 1, Jan. 2014, pp. 30–36, https://doi.org/10.1016/j.eururo.2013.06.042. ?Graff, Julie N., et al. “Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer.” Oncotarget, vol. 7, no. 33, July 2016, pp. 52810–17, https://doi.org/10.18632/oncotarget.10547. ?"
Other products related to enzalutamide
|CAS No.||Name of Impurity||Parent Drug||Catalogue No.|